Edgewise Therapeutics (NASDAQ:EWTX) received an updated price target from JPMorgan, with analysts at the firm raising their ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.

Our study investigated the brain circuits involved in psychosis-a condition characterized by delusions, hallucinations, ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

GOMEKLI™ is an oral, small molecule MEK inhibitor approved in the United States for the treatment of adult and pediatric ...

Tesla stock fell Monday amid a fresh TSLA price-target cut as the EV giant's favorability has slumped. TSLA stock dived over ...